Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Antibe Therapeutics Inc    ATE   CA0370251039

ANTIBE THERAPEUTICS INC (ATE)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/22 05:39:59 pm
0.325 CAD   -2.99%
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tsx Venture Exchange
01/16/2019 01/17/2019 01/18/2019 01/21/2019 01/22/2019 Date
0.33(c) 0.325(c) 0.335(c) 0.335(c) 0.325 Last
191 185 266 910 44 866 1 420 020 714 040 Volume
-1.49% -1.52% +3.08% 0.00% -2.99% Change
More quotes
Financials (CAD)
Sales 2019 9,22 M
EBIT 2019 -
Net income 2019 -7,16 M
Debt 2019 -
Yield 2019 -
Sales 2020 9,68 M
EBIT 2020 -
Net income 2020 -9,79 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 8,00x
Capi. / Sales2020 7,61x
Capitalization 73,7 M
More Financials
Company
Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and... 
More about the company
Latest news on ANTIBE THERAPEUTICS INC
10:00aANTIBE THERAPEUTICS : Receives Approval to Initiate Part Two of Phase 2B Dose-Ra..
AQ
2018ANTIBE THERAPEUTICS : Announces Successful Completion of Part One of Phase 2B Do..
BU
2018KWANGDONG PHARMACEUTICAL : licenses Canadian companys nonsteroidal anti-inflamma..
AQ
2018ANTIBE THERAPEUTICS : Announces Strategic Licensing Deal for Lead Drug in South ..
AQ
2018ANTIBE THERAPEUTICS : Enters Strategic Licensing Deal for Lead Drug in South Kor..
AQ
2018ANTIBE THERAPEUTICS : Reports Q1 2019 Interim Financial and Operating Results
AQ
2018ANTIBE THERAPEUTICS : Completes Share Issuance in Connection with Citagenix Cred..
AQ
2018ANTIBE THERAPEUTICS : Releases Secondary Endpoint Data from Recent Phase 2B Gast..
AQ
2018ANTIBE THERAPEUTICS : Reports 2018 Year-End Financial and Operating Results
AQ
2018ANTIBE THERAPEUTICS : Announces Results of Annual General and Special Meeting
AQ
More news
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart ANTIBE THERAPEUTICS INC
Duration : Period :
Antibe Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 1,40  CAD
Spread / Average Target 318%
EPS Revisions
Managers
NameTitle
Daniel Legault President, Chief Executive Officer & Director
Walter M. MacNee Chairman
Alain Wilson Chief Financial Officer
John Lawrence Wallace Director & Chief Scientific Officer
Roderick J. Flower Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ANTIBE THERAPEUTICS INC8.06%55
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS17.49%49 757
REGENERON PHARMACEUTICALS12.14%44 532
GENMAB-3.09%9 527
NEUROCRINE BIOSCIENCES, INC.28.18%8 300